Online citations, reference lists, and bibliographies.
← Back to Search

Radical Surgery For Mesothelioma

T. Treasure, D. Waller, S. Swift, J. Peto
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The epidemic is still to peak and we need more research to manage it One in every hundred men born in the 1940s will die of die of malignant pleural mesothelioma, which is almost exclusively a consequence of exposure to asbestos, with a lag time that is rarely less than 25 years and often more than 50 years from first exposure. Half of all cases are now aged over 70, with 80% in men. For a man first exposed as a teenager, who remained in a high risk occupation, such as insulation, throughout his working life, the lifetime risk of mesothelioma can be as high as one in five.w1 There are now over 1800 deaths per year in Britain (about one in 200 of all deaths in men and one in 1500 in women), and the number is still increasing.1 w2 As exposure in the United Kingdom continued until 1980 the peak of the epidemic is still to come, and we need a strategy to manage these patients. Asbestos was a valuable and versatile material and imports rose after the second world war when it was widely used as an insulator, in the manufacture of filters, cements, friction products, and as a fire retardant. It found a place in shipbuilding and industry and was used extensively in building in the form of light workable boards.2 It was a convenient partitioning material that …
This paper references



This paper is referenced by
10.1158/1078-0432.CCR-04-1450
Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study
A. Cesario (2005)
10.1016/S1155-195X(10)48015-9
Pleurésies néoplasiques : diagnostic et principes de prise en charge
Philippe Girard (2010)
10.1179/oeh.2004.10.2.212
The Epidemic of Asbestos-related Diseases in New Zealand
T. Kjellstrom (2004)
10.1016/J.JTCVS.2007.02.014
Ten traps for the unwary in surgical series: a case study in mesothelioma reports.
T. Treasure (2007)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
GLOBAL PANORAMA ON MESOTHELIOMA 2009
Laurie Kazan-Allen (2009)
10.1016/J.CCM.2006.01.006
Pathology of the pleura.
J. English (2006)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1201/B11349-19
Assessing Cardiothoracic Surgery: Practical Examples
T. Treasure (2011)
10.1136/thx.2006.066886
The epidemiology and treatment of mesothelioma in South East England 1985–2002
V. Mak (2007)
10.1097/01.CDR.0000282897.02516.56
The CT Appearances and Manifestations of Malignant Pleural Mesothelioma
Susan Cross (2007)
10.1016/j.athoracsur.2014.01.050
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
L. Spaggiari (2014)
10.1016/j.athoracsur.2009.05.036
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)
10.1080/14774003.2005.11667656
Community Views on Responding to a Local Asbestos Disease Epidemic: Implications for Policy and Practice*
A. LaMontagne (2005)
Work and health in the Latrobe Valley : community perspectives on asbestos issues
H. Walker (2004)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
Mesothelioma and Radical Surgery (MARS): a randomised controlled trial of extrapleural pneumonectomy for malignant pleural mesothelioma
T. Treasure (2011)
10.1016/J.LUNGCAN.2005.07.010
Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM)
A. Klabatsa (2006)
10.1179/107735207800244974
Building Safety—An International Perspective
Fiona Murie (2007)
10.2217/LMT.12.42
Doubt and its resolution in mesothelioma, pulmonary metastases and lung cancer
Tom Treasure (2012)
10.1055/s-2008-1039314
The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
A. Orki (2009)
10.2190/NS.18.3.j
Asbestos Disease in Australia: Looking Forward and Looking Back
A. LaMontagne (2008)
10.1016/B978-0-08-099359-1.00006-0
The Immaterial of Materials
J. Allen (2014)
10.1111/j.1440-1843.2011.02020.x
Facts, rumours and speculations about the mesothelioma epidemic
J. Van Meerbeeck (2011)
10.1196/annals.1371.042
The Economic Costs of Health Service Treatments for Asbestos‐Related Mesothelioma Deaths
A. Watterson (2006)
10.1038/nature02622
Genomes for medicine
D. Bentley (2004)
10.1111/j.1365-2354.2007.00912.x
'Hands of Time': the experience of establishing a support group for people affected by mesothelioma.
S. Moore (2008)
10.1016/j.ejcts.2009.08.016
Surgery for mesothelioma: MARS landing and future missions.
T. Treasure (2010)
10.1088/0031-9155/49/17/012
Methodology for lognormal modelling of malignant pleural mesothelioma survival time distributions: a study of 5580 case histories from Europe and USA.
R. Mould (2004)
Progress in the management of malignant pleural mesothelioma
M. Krzakowski (2005)
10.1093/ejcts/ezx122
Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma
Monica Casiraghi (2017)
10.1539/joh.48.309
24 Years of Pneumoconiosis Mortality Surveillance in Australia
D. Smith (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar